LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Начало・Списък с акции・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Затворен

1.1 -1.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.07

Максимум

1.1400000000000001

Ключови измерители
By Trading Economics
Приходи	1.7M -5.1M
Продажби	90K 90K
Марж на печалбата	-5,701.111
Служители	25
EBITDA	2.6M -4.9M

Дивиденти
By Dow Jones
Следващи печалби	27.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-6.9M 35M
Предишно отваряне	2.89
Предишно затваряне	1.1

Actinium Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.03.2026 г., 22:51 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18.03.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18.03.2026 г., 20:31 ч. UTC

Печалби

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18.03.2026 г., 23:31 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery -- Market Talk

18.03.2026 г., 22:49 ч. UTC

Пазарно говорене

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18.03.2026 г., 22:36 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18.03.2026 г., 22:24 ч. UTC

Печалби

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18.03.2026 г., 21:58 ч. UTC

Печалби

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18.03.2026 г., 21:40 ч. UTC

Пазарно говорене

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18.03.2026 г., 21:16 ч. UTC

Пазарно говорене

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18.03.2026 г., 21:00 ч. UTC

Значими събития в новините

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18.03.2026 г., 20:58 ч. UTC

Печалби

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18.03.2026 г., 20:41 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:29 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:25 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18.03.2026 г., 20:14 ч. UTC

Пазарно говорене

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18.03.2026 г., 20:09 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18.03.2026 г., 20:07 ч. UTC

Печалби

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18.03.2026 г., 20:06 ч. UTC

Печалби

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Gross Margin About 81% >MU

18.03.2026 г., 20:03 ч. UTC

Печалби

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Сравнение с други в отрасъла

Ценова промяна

Actinium Pharmaceuticals Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Actinium Pharmaceuticals Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.